Caris Molecular Intelligence™ is an evidence-guided tumour profiling service, which aims to help physicians select the best available therapy for each patient. It examines a broad range of established biomarkers using the best available technologies and with the help of a proprietary database, associates drugs that are more or less likely to benefit each individual patient. Using the MI Profile™ report, physicians are able to more easily translate the results from published clinical studies into individualised treatment plans.
- Thorough and Accurate Biomarker Analysis
- Correlates biomarker targets to therapeutic agents
- Informs treatment decisions through an actionable report
- Extensive Clinical Literature Assessment
- Actionable Biomarkers Found in 95% of cases
- Average of 25 clinically relevant results reported per patient
Since 2005, Caris Molecular Intelligence has helped more than 6,000 physicians in 58 countries worldwide, to manage therapeutic dilemmas for over 50,000 cancer patients with 150 different histology subtypes.
Read here about which patients are most suitable for tumour profiling, the Molecular Intelligence processand available profiling options.
Download a sample report to learn more about how Caris Molecular Intelligence results can help to inform treatment decisions.
For further details about sample requirements, laboratory processes, reimbursement and evidence proving the utility of molecular profiling, contact us.
+41 21 533 53 00 / +800 12 12 30 30 (Basel, Switzerland)
or
+79 854 425 929 (Moscow, Russia)
Frequently asked questions
What are the potential clinical benefits of Caris Molecular Intelligence?
Molecular Intelligence helps to build an individualised treatment plan when therapeutic ambiguities exist in patients with unresectable primary tumours or metastatic disease.
Caris Molecular Intelligence allows physicians to:
- Navigate among therapies with potential benefit
- Identify therapies which may not have been considered
- Determine drugs with potential lack of benefit
Which patients may be suitable for Caris Molecular Intelligence™?
Although Caris Molecular Intelligence is available for all solid tumours, including cancers of unknown primary, it is especially helpful when treating:
Rare tumours with limited prospective data to support treatment decisions, e.g.
Aggressive and Refractory Disease where there is limited time to select effective therapy, e.g.
- Melanoma
- Ovarian cancer
- Pancreatic cancer
- Triple Negative Breast Cancer
When Standard Treatment Options Have Failed and the patient maintains good performance status, but there is no guideline to support further treatment
What profiling options does Caris Molecular Intelligence provide?
Physicians can order Caris services to suit the needs of the individual patient.
MI Profile™
Multi-platform, pan-tumour biomarker analysis for therapeutic decision support in solid tumours including NGS mutational analysis of 34 genes for in-depth biomarker analysis.
How are Caris Molecular Intelligence results reported?
The ordering physician will receive all results in a clinically actionable report, called the MI Profile™ Report. The first page provides a summary of relevant therapies with potential benefit and potential lack of benefit, as well as associated clinical trials. Subsequent pages provide more in-depth results and analysis based on the biomarker results and published clinical literature. Finally, the report describes the levels of evidence associated with each identified therapeutic agent and provides a bibliography of published research relevant to each biomarker and therapy, as well as the full results of all biomarker tests performed.
How do I order Caris Molecular Intelligence for my patient?
The following items are required for Caris Molecular Intelligence evidence-guided tumour profiling:
- Completed requisition form signed by the ordering physician.
- Most recent clinical history or patient notes if available.
- Pathology report corresponding to the specimen submitted for profiling. Please check the sample identification number match.
Caris Molecular Intelligence is available to purchase privately in all European markets. Individual insurance companies, clinics and other organisations is most countries have agreed to pay for the service on application.
Please ask our customer services staff for information on how to apply for payment.
- A malignant tumour specimen. As tumour biomarkers can change over time and with treatment, we recommend analysis on recently collected specimen.
Where can I get additional information?
If you have further questions about Caris Life Sciences or Caris Molecular Intelligence, please call or e-mail our Customer Services team at
+800 12 12 3030 (Basel, Switzerland) or
+79 854 425 929 (Moscow, Russia)
EUCustomerservices@carisls.com, or visit our website at www.carislifesciences.eu.
Molecular Intelligence™ Service, from Caris Life Sciences®, provides evidence-based tumour information that associates biomarker status to agents with potential clinical benefit or potential lack of clinical benefit. Agents associated with clinical benefit are presented based on NCCN Compendium™ inclusion, relevance of tumour type, level of published evidence and strength of biomarker expression. Report information must be considered in conjunction with all other relevant information in respect of a given patient before determining the appropriate course of treatment. The selection of agents for re-treatment from prior chemotherapy regimens lies with the treating physician and must be done with careful consideration. Caris Molecular Intelligence Service was developed and its performance characteristics were determined by Caris Life Sciences, a medical laboratory CLIA-certified in compliance with the U.S. Clinical Laboratory Amendment Act of 1988 and all relevant U.S. state regulations. Caris Molecular Intelligence Service has not been approved by the United States Food and Drug Administration.
2013 © Caris Life Sciences and affiliates. All rights reserved.
The Caris Molecular Intelligence Process
Caris Molecular Intelligence combines a thorough and accurate analysis of the biomarker profile of a patient’s tumour with extensive clinical literature review to inform treatment choices when standard treatment is not an option.
Oncologists submits Tumour Sample
Caris laboratory staff interrogates the patient’s tumour with the most relevant and advanced technologies and deliver comprehensive BIOMARKER RESULTS
The Caris team analyse the biomarker results and match them with PUBLISHED EVIDENCE in the Caris database
The REPORT is populated to include biomarker results, treatment associations and clinical citation.
The ONCOLOGIST uses the report to inform TREATMENT DECISIONS
About Caris Life Science
Transforming Healthcare into Human Care
Caris Mission
At Caris Life Sciences®, we serve hundreds of patients worldwide each day through our sophisticated diagnostic, prognostic and theranostic services. We believe that better diagnostic information can lead to better treatments and ultimately to better outcomes for patients with cancer and other complex diseases.
Caris Scientific Excellence
To ensure services of the highest quality and clinical relevance, Caris employs a dedicated team of highly trained clinical and medical experts who oversee and manage laboratory performance, the quality of testing, and the biomarker evidence review process.
Caris Laboratory Excellence
Caris offers a range of clinically relevant, diagnostic assays and laboratory testing services that are performed in our 5,600 square meter, Phoenix-based laboratory that is licensed and validated under the Clinical Laboratories Improvement Act (CLIA) and by New York State.
The Caris Life Sciences® laboratories hold the following certifications:
- Caris MPI: CLIA: 03D1019490
- NY Lab License CMP
- ISO 15189
Russian version
